Video

Treating Early Breast Cancer


 

The 10-year follow-up data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial continue to show that the adjuvant anastrozole significantly reduces the rate of breast cancer recurrence and secondary primary breast cancer in comparison with tamoxifen in postmenopausal, hormone receptor-positive patients, Dr. Aman Buzdar explains.

Recommended Reading

Bisphosphonates May Reduce Breast Cancer Risk
MDedge Hematology and Oncology
Mammography Screening Before Age 50
MDedge Hematology and Oncology
Breast Cancer Evolves
MDedge Hematology and Oncology
Triple-Negative Breast Cancer and BRCA Mutations
MDedge Hematology and Oncology
Shoulder Discomfort
MDedge Hematology and Oncology
Acupuncture in Breast Cancer
MDedge Hematology and Oncology
Adjuvant Aromatase Inhibitors
MDedge Hematology and Oncology
TEAM Trial
MDedge Hematology and Oncology
Commentary on TEAM Trial
MDedge Hematology and Oncology
SLN Biopsy
MDedge Hematology and Oncology